CVS, UnitedHealth, Cigna Ask FTC's Khan to Disqualify Herself From Insulin Case
NEW YORK (Reuters) -CVS Health, UnitedHealth Group and Cigna have asked U.S. Federal Trade Commission chair Lina Khan and commissioners Rebecca Kelly Slaughter and Alvaro Bedoya to disqualify themselves from an FTC lawsuit that has accused the companies of unlawfully inflating insulin prices.
Wyden and Brown pointed to CVS (CVS) and Cigna’s (CI) manufacturing subsidiaries, Cordavis and Quallent Pharmaceuticals. Established to produce biosimilars against AbbVie’s (ABBV) Humira in ...
CVS Caremark said in a statement that it's drugmakers who are increasing the prices of drugs rather than PBMs. Cigna Chief Legal Officer Andrea Nelson said in a statement that the FTC's lawsuit is ...
FTC’s lawsuit against PBMs puts UnitedHealth, CVS, and Cigna stocks in focus for investors seeking stability. Cigna could see more price movement than UNH and CVS, thanks to its focused ...
following similar moves by rivals Cigna (NYSE:CI) and CVS Health (NYSE:CVS). However, the company added that it will devise a path to offer coverage for Humira until the biosimilars win the ...
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
The Federal Trade Commission (FTC) is suing pharmacy benefit managers CVS Health (), Cigna Group (), and UnitedHealth over insulin prices, claiming that they have been artificially inflating costs ...
The FTC has filed a formal complaint accusing CVS, Cigna, and UnitedHealth of engaging in anti-competitive practices that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback